Meningitis vaccine fails to prevent gonorrhea in rigorous randomized trial
A well-designed hope has been put to rest. The meningococcal B vaccine 4CMenB (Bexsero), which observational studies had suggested could offer 30–40% protection against gonorrhea, has shown zero efficacy in the first large-scale randomized controlled trial designed specifically to test that question.
The results, published July 9 in the New England Journal of Medicine and led by Prof. Kate Seib of Griffith University and Prof. Andrew Grulich of the Kirby Institute at UNSW Sydney, are unambiguous: the vaccine had no effect.
What the trial found
The GoGoVax trial enrolled 620 participants, cisgender men, transgender men, transgender women, and non-binary individuals who have sex with men, across seven sexual health clinics in three Australian states (New South Wales, Victoria, Queensland). All participants had a history of gonorrhea or syphilis within the prior 18 months and were at high ongoing risk. The per-protocol analysis included 587 participants: 296 who received two doses of 4CMenB three months apart, and 291 who received saline placebo.
Over 24 months of follow-up with STI testing every three months, the results were stark:
- Vaccine arm: 160 participants had at least one gonorrhea infection, an incidence rate of 48.1 per 100 person-years
- Placebo arm: 155 participants, an incidence rate of 47.9 per 100 person-years
- Incidence rate ratio: 1.01 (95% CI 0.80–1.26)
- Vaccine efficacy: −0.5% (95% CI −26.16% to 19.93%)
Annual incidence was approximately 48% in both arms. The vaccine did nothing.
Why the observational studies may have misled
The hope that a meningitis vaccine could help against gonorrhea was not without foundation. Neisseria meningitidis and Neisseria gonorrhoeae are close bacterial cousins, both are Gram-negative diplococci sharing 80–90% genome identity, and their outer membrane proteins overlap substantially. The 4CMenB vaccine contains three recombinant protein antigens plus outer membrane vesicles from a New Zealand outbreak strain, designed to elicit antibodies against meningococcus.
Beginning in 2017, a series of observational studies told a compelling story. Petousis-Harris et al. in The Lancet reported that the New Zealand MeNZB vaccine reduced gonorrhea risk by 31%. Subsequent studies from the United States, South Australia, and a 2024 meta-analysis found 32–47% effectiveness. The evidence was consistent enough that the UK’s Joint Committee on Vaccination and Immunisation (JCVI) recommended in November 2023 that England’s NHS offer 4CMenB to gay and bisexual men at high risk, and Galicia, Spain followed in June 2025.
But observational data cannot fully eliminate confounding. People who seek a meningitis vaccine may differ systematically from those who do not, in healthcare engagement, risk awareness, testing frequency, or sexual behavior, and these differences can masquerade as vaccine effects.
The biology of a mismatch
Seib and colleagues offered several explanations for why the vaccine may have failed in this population specifically.
First, the trial enrolled extremely high-risk men, 90% had prior gonorrhea. Previous gonorrhea infections generate antibodies against the bacterial protein Rmp (reduction-modifiable protein), which can block other vaccine-induced antibodies from binding. Pre-existing Rmp-blocking antibodies may have neutralized any cross-protective effect the vaccine might offer in a lower-risk, less-exposed population.
Second, 4CMenB protects against meningococcal disease primarily by preventing Neisseria meningitidis from entering the bloodstream, it does not eliminate throat carriage. Gonorrhea is a purely mucosal infection, and a vaccine designed to generate systemic bactericidal antibodies may be mechanically ill-suited to a pathogen that never enters the bloodstream.
Two prior smaller randomized trials had also found no statistically significant effect. The DOXYVAC trial in France (Molina et al., 2024, Lancet Infectious Diseases) found a non-significant 22% reduction in an open-label, prematurely ended study. The MenGO trial in Australia (N=130) reported an incidence rate ratio of 0.78 (95% CI 0.40–1.51). The null result in GoGoVax, with 587 evaluable participants, brings the randomized evidence decisively into alignment.
What this means
The public health implication is significant. Gonorrhea is the second most common bacterial STI worldwide, with an estimated 82 million new cases annually. Rising antimicrobial resistance, Neisseria gonorrhoeae has developed resistance to every first-line antibiotic deployed against it, makes an effective vaccine urgently needed.
GoGoVax closes one promising observational lead. Several trials are ongoing, including BIYELA in South Africa (1,100 cisgender women, expected January 2027) and a larger NIAID trial across the United States, Malawi, and Thailand (2,200 men and women, expected October 2026). Whether any existing meningococcal vaccine formulation can protect against gonorrhea in a less-exposed population, or whether a gonorrhea-specific vaccine is the only viable path, remains an open question.
Sources:
1. Seib, K. & Grulich, A. et al. “Efficacy of 4CMenB Vaccine to Prevent Gonorrhea in Gay and Bisexual Men (GoGoVax).” New England Journal of Medicine (2026). DOI: 10.1056/NEJMoa2516739
2. Science AAAS. “Study dampens hope that meningitis vaccine can also prevent gonorrhea.” July 9, 2026. https://www.science.org/content/article/study-dampens-hope-meningitis-vaccine-can-also-prevent-gonorrhea
3. Petousis-Harris, H. et al. “Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhea in New Zealand.” The Lancet 390, 1603–1610 (2017).
4. Abara, W.E. et al. “Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhea.” The Journal of Infectious Diseases (2024).
5. Molina, J.M. et al. (DOXYVAC). The Lancet Infectious Diseases (2024).